Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Coenzyme Q10,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Pharma Nord
Deal Size : Inapplicable
Deal Type : Inapplicable
A Danish Pragmatic Randomized Trial of Nutritional Supplements in Heart Failure
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 19, 2024
Lead Product(s) : Coenzyme Q10,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Pharma Nord
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Isura
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of Different CoQ10 Formulations
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 30, 2023
Lead Product(s) : Coenzyme Q10,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Isura
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10,Vitamin E
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Sanofi Completes Acquisition of Qunol®
Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the US.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
September 29, 2023
Lead Product(s) : Coenzyme Q10,Vitamin E
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Coenzyme Q10,Vitamin E
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Sanofi to Acquire Qunol®, a Fast-Growing U.S. Brand in the Healthy Aging Segment
Details : Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
July 27, 2023
Lead Product(s) : Coenzyme Q10,Vitamin E
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Coenzyme Q10,Inapplicable
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Biovis d.o.o.
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparative Single-dose Bioavailability Clinical Study of Different Coenzyme Q10 Products
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 09, 2022
Lead Product(s) : Coenzyme Q10,Inapplicable
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Biovis d.o.o.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Kaneka Pharma Europe N.V. | Sanatórium of Dr. Guhr, n.o.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
January 05, 2022
Lead Product(s) : Coenzyme Q10,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Kaneka Pharma Europe N.V. | Sanatórium of Dr. Guhr, n.o.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10,Selenium
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Pharma Nord
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
November 19, 2021
Lead Product(s) : Coenzyme Q10,Selenium
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Pharma Nord
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10,Caspofungin
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Undisclosed
Sponsor : Clarus
Deal Size : $40.8 million
Deal Type : Licensing Agreement
Details : Under the licensing agreement Clarus will develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans with Coenzyme-Q10 (Ubiquinone).
Product Name : Ubiquinone
Product Type : Enzyme
Upfront Cash : $0.4 million
September 16, 2021
Lead Product(s) : Coenzyme Q10,Caspofungin
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Undisclosed
Sponsor : Clarus
Deal Size : $40.8 million
Deal Type : Licensing Agreement
Lead Product(s) : Coenzyme Q10,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : University of Aarhus | Pharma Nord
Deal Size : Inapplicable
Deal Type : Inapplicable
Coenzyme Q10 as Treatment for Long Term COVID-19
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
July 13, 2021
Lead Product(s) : Coenzyme Q10,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : University of Aarhus | Pharma Nord
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coenzyme Q10,Vitamin K1,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 12, 2021
Lead Product(s) : Coenzyme Q10,Vitamin K1,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable